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        IL-1      (IL-1F1) and IL-1      (IL-1F2) are related 
cytokines involved in infl  ammation in a variety 
of tissues and diseases (  1, 2  ). Both are ligands 
for a heterodimeric receptor composed of the 
type 1 IL-1R (IL-1R) and IL-1R accessory 
protein (AcP; IL-1RAcP) (  3  ). Either IL-1      or 
      can bind to IL-1R, but this alone does not 
activate signal transduction. Binding of the lig-
ands to IL-1R results in recruitment of AcP to 
the complex, resulting in juxtaposition of intra-
cellular IL-1R and AcP TIR (Toll/IL-1R) 
domains, and activation of signal transduction 
(  2  ). Another related ligand, IL-1R antagonist 
(IL-1ra and IL-1F3), competes with IL-1      and 
-1      for binding to IL-1R. The IL-1R  –  IL-1ra 
complex cannot recruit AcP, and is incapable 
of signaling (  4  ). Type II IL-1R and a soluble 
form of AcP are involved in additional layers of 
IL-1 regulation (  5, 6  ). 
  IL-18 (IL-1F4) is another IL-1 ligand fam-
ily member involved in infl  ammation (  7, 8  ). 
IL-18R and -18RAcPL comprise the func-
tional IL-18R (  9  ). A natural antagonist of this 
system, IL-18  –  binding protein (IL-18bp), is 
not an IL-1 family member and acts by seques-
tering IL-18, preventing it from binding to its 
receptor (  10  ). Therefore, IL-18bp and -1ra act 
to antagonize their respective cytokines by dis-
tinct mechanisms. 
  Several IL-1 ligand and receptor family mem-
bers have been implicated in cutaneous infl  am-
mation. Transgenic mice expressing   IL1A       from 
the keratin 14 (K14) promoter develop focal 
infl  ammatory skin lesions, hair loss, and scaling. 
At the histological level, the transgenic mice have 
hyperkeratosis and dermal infl  ammation mainly 
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  The interleukin (IL)-1 family members IL-1     , -1     , and -18 are potent infl  ammatory cyto-
kines whose activities are dependent on heterodimeric receptors of the IL-1R superfamily, 
and which are regulated by soluble antagonists. Recently, several new IL-1 family members 
have been identifi  ed. To determine the role of one of these family members in the skin, 
transgenic mice expressing   IL1F6   in basal keratinocytes were generated.   IL1F6   transgenic 
mice exhibit skin abnormalities that are dependent on IL-1Rrp2 and IL-1RAcP, which are 
two members of the IL-1R family. The skin phenotype is characterized by acanthosis, hyper-
keratosis, the presence of a mixed infl  ammatory cell infi  ltrate, and increased cytokine and 
chemokine expression. Strikingly, the combination of the IL-1F6 transgene with an   IL1F5   
defi  ciency results in exacerbation of the skin phenotype, demonstrating that IL-1F5 has 
antagonistic activity in vivo. Skin from   IL1F6   transgenic,   IL1F5        /               pups contains intracor-
neal and intraepithelial pustules, nucleated corneocytes, and dilated superfi  cial dermal 
blood vessels. Additionally, expression of   IL1RL2  ,   -1F5  , and   -1F6   is increased in human 
psoriatic skin. In summary, dysregulated expression of novel agonistic and antagonistic IL-1 
family member ligands can promote cutaneous infl  ammation, revealing potential novel 
targets for the treatment of infl  ammatory skin disorders. 2604 OPPOSING ACTIVITIES OF IL-1F6 AND IL-1F5 IN SKIN | Blumberg et al.
composed of macrophages, but no alteration in epidermal 
thickness (  11  ). Transgenic mice expressing   IL18   from the ker-
atin 5 promoter exhibit many features of atopic dermatitis, 
including acanthosis; an infi  ltrate composed of eosinophils, 
neutrophils, and mast cells; an increase in serum IgE levels; 
and an increase in B cells in the draining lymph node (  12  ). 
In a BALB/c genetic background,   IL1RN  -defi  cient mice have 
histological features in common with psoriasis (  13  ). Mice de-
fi  cient in   IL1R1  ,   IL1RAP  ,   IL18R1  , and   IL18RAP   have no 
overt skin abnormalities (  14  –  18  ). 
  Genes encoding several IL-1  –  related ligands (from   IL1F5   
to   IL1F10  ) have been discovered and map to human chromo-
some 2q, the same locus as   IL1A      ,   -1B      , and   -1RN   (  1, 19  –  25  ). 
These IL-1F ligands lack signal sequences, and only IL-1F7 
contains a proregion. Phylogenetic analysis indicates that 
  IL1F5   and   -1F10   are most closely related to   IL1RN   (  24, 25  ). 
  IL1F6  ,   -1F  8, and   -1F9   comprise a separate triplet branch of 
the phylogenetic tree. 
  There are now 10 known members of the IL-1R family 
(  2  ). IL-1Rrp2 (RP2) was originally identifi  ed as an IL-1R 
family member expressed in the brain (  26  ). IL-1F9 was dem-
onstrated to activate signal transduction in an RP2-depen-
dent manner (  27  ). In addition, IL-1F9 activation of RP2 was 
antagonized by IL-1F5. These results have been extended by 
the demonstration that IL-1F6 and -1F8, in addition to IL-
1F9, activate signal transduction pathways and require both 
RP2 and AcP (  28  ). Quantitative RT-PCR analysis indicates 
that   IL1F6  ,   -1F8  , and   -1F9   are expressed in a restricted 
manner, primarily in the skin and in other epithelial tissues, 
whereas   IL1RL2   and   IL1RAP   are more widely expressed 
(unpublished data) (  28  ). 
  We report that transgenic expression of   IL1F6   in basal 
keratinocyte cells results in cutaneous alterations in both the 
  Figure 1.     K14    /IL1F6         transgenic pups have skin abnormalities. 
(A) K14  /IL1F6   transgenic pups have fl  aky skin, ringtail, and are runted. The 
gross phenotype of a K14  /IL1F6   transgenic  (Tg      ) pup and a nontransgenic 
(Tg          ) cagemate at 7 d of age is shown. (B) Skin from K14  /IL1F6   transgenic 
pups is hyperkeratotic, acanthotic (increased epidermal thickness), and 
contains a dermal infl  ammatory cell infi  ltrate. HE staining of skin from a 
K14  /IL1F6   Tg       and  Tg          pup at 7 d of age is shown. (C) Skin from K14  /IL1F6  
transgenic pups has increased expression of keratin 6 and ICAM-1, and an 
increased number of BM8         macrophage,  CD205       Langerhans or dermal 
dendritic cells, and CD3         T lymphocytes relative to skin from nontrans-
genic littermate control pups. CD205         staining most likely represents 
Langerhans cells, as the majority of the signal is epidermal. IHC staining 
of skin from K14  /IL1F6   Tg       and  Tg          pups at 7 d of age with specifi  c anti-
bodies is shown. Bar, 100      m. (D) Chemokines and cytokine protein levels 
are elevated in the skin of K14  /IL1F6   transgenic pups compared with non-
transgenic littermate pups. Skin was isolated from 7-d-old K14  /IL1F6   Tg      
and Tg           pups, protein extracts were prepared, normalized to total protein, 
and analyzed by Rules Based Medicine MAP profi  ling. MIP2, CXCL8 (IL-8); 
GCP2, CXCL6; MCP-3, CCL7. (E) Epidermal thickness is increased in the 
skin of K14  /IL1F6   transgenic pups at P5, 7, and 10 compared with non-
transgenic cagemate control pups. Skin was isolated from K14  /IL1F6   Tg      
and Tg           pups, stained with HE, and epidermal thickness was determined 
by histomorphometric analysis. Error bars in C and D represent the mean       
the SD. *, P           0.05; **, P           0.01; ***, P           0.001.   
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between P7 and 21; silencing of the  IL1F6   transgenic expression, 
decreased expression of the required RP2 and/or AcP recep-
tor subunits (see   Fig. 3  ), and increased expression of the IL-
1F5 antagonist (see   Fig. 4  ). Quantitative RT-PCR analysis 
was performed on   IL1F6  ,   IL1RL2  ,   IL1RAP  , and   IL1F5   in 
the skin from transgenic and nontransgenic pups at P1, 3, 5, 
7, 10, 14, and 21.   IL1F6   mRNA is expressed at higher levels 
in transgenic pup skin than in the nontransgenic pup skin at 
all time points (  Fig. 2 A  ).   However, transgenic   IL1F6   ex-
pression decreases over the 21-d time course. Expression lev-
els of   IL1F5  ,   -1F8  , and   -1F9   are increased in the K14/  IL1F6   
transgenic skin relative to the nontransgenic skin, and de-
creased from P1 to P21 in parallel with   IL1F6   transgene ex-
pression (  Fig. 2 A  ).   IL1RL2   mRNA levels are slightly higher 
in transgenic skin than in nontransgenic skin at P1 and 3, but 
not at later time points (  Fig. 2 B  ).   IL1RAP   mRNA levels are 
not altered at any time point by the presence of the transgene 
(  Fig. 2 B  ). Expression of   IL23A  ,   CSF2  ,   TNF      ,   IL1A      ,   CCL2  , 
  KRT14  ,   CXCL2  ,   HBEGF  , and   AREG   mRNA was in-
creased at specifi  c time points in the transgenic skin, relative 
to the nontransgenic control skin (  Fig. 2 C  ). However, their 
expression decreases as K14/  IL1F6   transgene expression di-
minishes (  Fig. 2 C  ). Therefore, decreased expression of the 
  IL1F6   transgene,   IL1F8  ,   IL1F9  ,   IL1RL2  , and infl  ammatory 
cytokines and chemokines is observed over the fi  rst 3 wk 
of age. 
  To further characterize the decreased expression of the 
K14/  IL1F6   transgene over time, IHC was performed on IL-
1F6 and K14. The following three time points were selected 
for analyses: P1 (initiation of transgene-dependent expression 
changes), P5 (peak of increased epidermal thickness induced 
by transgene expression), and P10 (after resolution of the skin 
phenotype has begun). Expression of IL-1F6 was observed 
throughout the epidermis at P1 and P5 in the transgenic skin, 
with the highest levels observed in the superfi  cial epidermis 
(  Fig. 2 D  ). Expression of IL-1F6 in nontransgenic pup skin 
was only in the superfi  cial layer at P1 and P5. In contrast, IL-
1F6 expression in transgenic skin at P10 was only observed in 
the superfi  cial epidermis, and it was similar in intensity to the 
endogenous, nontransgenic IL-1F6 level. To investigate ex-
pression of a skin marker at these same time points, we chose 
K14, as its promoter was used to drive IL-1F6 expression in 
the transgenic mice. K14 protein is found throughout the 
epidermis at P1 and 5 in transgenic skin, although a predomi-
nance of basal layer expression was observed at P5 (  Fig. 2 E  ). 
However, K14 protein was only observed in the basal layer 
in the transgenic skin at P10, which is its normal localization 
as shown in the nontransgenic skin (  Fig. 2 E  ). Therefore, it 
appears that   IL1F6   transgene expression is silenced in parallel 
with the phenotypic resolution. 
  Receptor requirement for K14  /IL1F6   skin phenotype 
  RP2 and AcP were shown to be required for activation of 
signal transduction in vitro by IL-1F6 (  28  ). To determine 
whether these receptor subunits were required for the skin 
alterations in K14  /IL1F6   pups, transgenic mice were crossed 
epidermis and dermis. Importantly, we demonstrate that the 
severity of the skin abnormalities is increased in   IL1F5    –  defi  -
cient mice, providing genetic evidence that IL-1F5 possesses 
antagonistic activity in vivo. We also demonstrate that   IL1RL2  , 
  IL1F5  , and   IL1F6   expression is increased in human psoriatic 
skin, thus suggesting a possible connection between the mouse 
skin phenotype and human pathophysiology. 
    RESULTS   
  Expression of   IL1F6   in skin results in cutaneous 
infl  ammation 
  The human K14 promoter was used to express mouse   IL1F6   
in basal keratinocytes in transgenic mice. Nine founders were 
obtained, one of which had severe skin abnormalities and was 
killed. This mouse had the highest   IL1F6   expression in skin 
of the founders. The next four highest expressers were devel-
oped into lines, all of which had a similar gross phenotype. 
The studies reported in this work were performed on a 
line with at least 70-fold higher mRNA levels in skin relative 
to the endogenous   IL1F6   mRNA level (unpublished data). 
K14  /IL1F6   pups were small, had fl  aky skin, and developed 
ringtail (  Fig. 1 A  ).   The skin phenotype was fi  rst observable at 
postnatal day (P) 5, was most severe at P7, and was overtly 
resolved by P21. However, recurrence of skin lesions, pre-
dominantly on the face, snout, and ears, developed in K14  /
IL1F6   mice at 6 mo of age. 
  Histological analysis on transgenic pups at P7 demonstrated 
acanthosis, hyperkeratosis, and a mixed infl  ammatory cell 
  infi  ltrate in the dermis composed mainly of neutrophils, macro-
phages, and lymphocytes (  Fig. 1 B  ). Histological changes in 
keratinocytes and immune cells were analyzed by immunohisto-
chemistry (IHC). Increased immunoreactivity was observed in 
markers for keratinocyte hyperproliferation (keratin 6), macro-
phages (BM8), epidermal Langerhans and dermal dendritic 
cells (CD205), infl  ammation (intercellular adhesion molecule 1 
[ICAM-1]), and T lymphocytes (CD3;   Fig. 1 C  ). Levels of a 
variety of cytokines and chemokines in skin protein extracts 
were compared in 1-wk-old K14  /IL1F6   pups and their non-
transgenic littermates. Elevated levels of GM-CSF, MIP-2, 
GCP-2, and MCP-3 were observed in the transgenic skin 
relative to the nontransgenic control skin (  Fig. 1 D  ). 
  To determine how the skin phenotype develops, we 
compared skin from K14  /IL1F6   pups to their nontransgenic 
littermates at 1, 3, 5, 7, 10, 14, and 21 d after birth by histo-
pathological analysis. During this time period, the mouse 
epidermis normally decreases in epidermal thickness. The 
maximal increase in epidermal thickness in K14  /IL1F6   skin 
relative to nontransgenic skin was observed at P5 (  Fig. 1 E  ). 
In contrast, the presence of a mixed dermal infl  ammatory in-
fi  ltrate reached its peak at P7 (unpublished data). Resolution 
of the histopathological skin abnormalities began between P7 
and 10, and progressed to normal skin by P21. 
  Resolution of the K14/  IL1F6   skin phenotype 
  We considered several possible hypotheses to explain the 
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  Figure 2.     Quantitative RT-PCR and IHC analyses demonstrate reduced expression of IL-1F6 as the skin phenotype resolves. (A) Expression of 
  IL1F5 ,   -1F6 ,   -1F8  , and   -1F9   in the skin decreases over the P1  –  21 time course. (B) Expression of   IL1RL2   is elevated in transgenic skin relative to control skin 
at P1 and 3. Expression of   IL1RL2   at P5  –  21, and expression of   IL1RAP   from P1  –  21 is not different in transgenic and nontransgenic skin. (C) Expression of 
  IL23A ,   CSF2 ,   TNF  , IL1A   ,   CCL2 ,   KRT14 ,   CXCL2 ,   TGA2   ,   HBEGF  , and   AREG   is given in both transgenic and nontransgenic skin from P1 to 21. Total skin RNA was 
isolated from K14/  IL1F6   transgenic and nontransgenic pups (  n        3) and was analyzed by quantitative RT-PCR. Expression of specifi  c genes is relative to JEM VOL. 204, October 29, 2007 
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with pups treated with a control antibody.   Additionally, 
K14/  IL1F6  ,   TNFRSF1A      −  /  −    (p55) pups had a similar decrease 
in epidermal thickness and dermal infi  ltrate compared with 
K14/  IL1F6  ,   TNFRSF1A    +/+   (p55) pups (unpublished data). 
Therefore, TNF-      and   TNFRSF1A   are not required for 
the K14  /IL1F6   skin phenotype, but they do modulate the 
severity of the skin lesion, especially the amount of dermal 
infl  ammation. 
  Expression of chemokines involved in neutrophil mobili-
zation is elevated in the skin of K14  /IL1F6   pups (  Fig. 1 D 
and Fig. 2 C  ), leading to the recruitment of neutrophils to 
the dermis (  Fig. 1 B  ). To understand the functional role of 
neutrophils in the transgenic skin, pups were treated with the 
neutrophil-depleting antibody anti-Gr1 (  31  ) or with an iso-
type-matched control antibody. Most of the neutrophils in 
the skin were depleted with anti-Gr1 treatment relative to 
those treated with the control antibody (  Fig.4 D  ). However, 
some neutrophils were still detected in the skin. Decreased 
neutrophils numbers with anti-Gr1 treatment resulted in a 
lower infl  ammation severity ranking (  Fig. 4 C  ), but there was 
little eff  ect on the epidermal thickness (unpublished data). 
Because of incomplete depletion, we cannot prove that neu-
trophils are dispensable for the generation of the IL-1F6  –
  induced skin abnormalities. However, we can conclude that 
elimination of the majority of skin neutrophils primarily has 
its eff  ect on the dermal infi  ltrate. 
  There is an increase in CD3  +   T lymphocytes in the skin of 
K14/IL-1F6 pups compared with the skin of nontransgenic 
littermates (  Fig. 1 C  ). To determine the role that lymphocytes 
play in the generation of the skin phenotype, the K14  /IL1F6   
transgene was crossed onto a   RAG2  -defi  cient background 
(  32  ). IHC with anti-CD3 demonstrated that T lymphocytes 
were indeed absent in the skin of K14  /IL1F6  ,   RAG2      −  /  −    pups 
(  Fig. 4 E  ). No diff  erences were observed in the skin at the 
gross level, and only a slightly decreased severity between 
K14  /IL1F6  ,   RAG2      −  /  −    pups and K14  /IL1F6  ,   RAG2    +/  −    pups 
was noted histologically. In addition, the expression of the in-
fl  ammatory marker ICAM-1 was not altered (  Fig. 4 E  ). There-
fore, mature lymphocytes are also not required for the observed 
skin abnormalities in the K14  /IL1F6   transgenic pups. 
  Exacerbation of the K14  /IL1F6   skin phenotype in   IL1F5      −  /  −    
and   -1F5    +/  −    mice 
  IL-1F5 antagonizes the RP2-dependent signal transduction 
in vitro in response to IL-1F9 (  27  ). Because IL-1F6 has similar 
activity to IL-1F9 in vitro (  28  ), we tested whether IL-1F5 can 
also block the eff  ect of this ligand. IL-1F5 antagonized IL-1F6 
activity in a variety of in vitro assays (unpublished data). Sub-
stantial inhibition was observed at an equimolar IL-1F5/-1F6 
ratio, which is consistent with published results (  27  ). 
into   IL1RL2  - or   IL1RAP  -defi  cient backgrounds. Mice defi  -
cient in   IL1RL2   were generated as described in the Materials 
and methods. Mice lacking   IL1RL2   were born at the pre-
dicted Mendelian ratios from heterozygous intercrosses and 
displayed no overt phenotypes on C57BL/6; 129 hybrid, 
C57BL/6, or FVB genetic backgrounds. Mice defi  cient in 
  IL1RL2   or   IL1RAP   have normal skin in an unchallenged 
context. Transgenic pups carrying the K14  /IL1F6   transgene 
and lacking the receptor subunit (    −  /  −   ) were compared with 
littermates that were transgenic and were heterozygous (  +/  −   ) 
or wild-type (  +/+  ) for the receptor subunit. Expected Mende-
lian ratios were observed for all crosses. Pups were scored by 
their gross phenotype and by histopathological analyses at P7. 
Nontransgenic pups had normal skin, whereas transgenic 
pups that were   IL1RL2    +/+  ,   IL1RAP    +/+  ,   IL1RL2    +/  −   , or   IL-
1RAP    +/  −    had a skin phenotype. However, transgenic pups 
lacking   IL1RL2   or   IL1RAP   did not exhibit a phenotype 
(  Fig. 3, A and B  ).   Therefore,   IL1RL2   and   IL1RAP   are re-
quired for the K14  /IL1F6   skin phenotype. 
  To provide further support for the essential role of RP2 in 
mediating IL-1F6 activity, intraperitoneal injections of a neu-
tralizing monoclonal antibody against mouse RP2 (M616) 
and an isotype-matched control antibody in K14  /IL1F6   new-
born pups were performed. Half of each litter was injected 
with 50      g M616 on P1, 3, and 5, whereas the rest of the lit-
ter was marked and injected with 50      g control antibody. 
Pups were killed on P7, and were subjected to genotyping 
and histological analyses. The skin phenotype was blocked by 
M616 administration, but not by treatment with a control anti-
body, confi  rming the RP2 requirement (  Fig. 3 C  ). 
  The K14  /IL1F6   transgene was crossed into an   IL1R1  -
defi  cient background to determine if this receptor is required 
for the skin phenotype.   IL1R1  -defi  cient mice have no skin 
abnormalities in an unchallenged context. Expected Mende-
lian ratios were observed. K14  /IL1F6   transgenic pups lack-
ing   IL1R1   exhibit a skin phenotype similar in severity to 
K14  /IL1F6   pups containing   IL1R1   (  Fig. 3 D  ). Therefore, 
  IL1R1   is not required for the K14  /IL1F6   skin phenotype. 
  Immune requirements for the K14  /IL1F6   skin phenotype 
  TNF-      is an important cytokine in skin infl  ammation, and 
its blockade is an eff  ective treatment for psoriasis (  29  ). TNF-      
mRNA is elevated in the skin of K14/  IL1F6   pups from P1-
P14 (  Fig. 2 C  ). To determine if the K14  /IL1F6   transgenic 
skin phenotype is dependent on TNF-     , K14  /IL1F6   pups 
were treated with TN3-19.12 (  30  ), a neutralizing antibody 
against mouse TNF-     . Transgenic pups treated with anti  –
  TNF-      have a statistically signifi  cant decrease in epidermal 
thickness (  Fig. 4 A  ) and a much more dramatic reduction in 
the amount of dermal immune infi  ltrate (  Fig. 4 B  ) compared 
     -actin. *, P           0.05; **, P           0.01; ***, P           0.001. Error bars in A–C represent the mean   the SD. (D) Protein expression of IL-1F6 in K14/  IL1F6   transgenic 
pup skin is elevated at P1 and P5 relative to nontransgenic control skin, but is decreased to the endogenous level by P10. (E) K14 protein was detected 
throughout the epidermis in transgenic pups at P1 and 5, and is observed only in the basal layer at P10. Skin samples were fi  xed in neutral buffered for-
malin, sectioned, analyzed by IHC using a monoclonal antibody against mouse IL-1F6 or a polyclonal antibody against K14. Bar, 100      m.   
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  To study whether IL-1F5 can aff  ect the severity of the 
K14  /IL1F6   skin phenotype, mice defi  cient in   IL1F5   were 
generated (see Materials and methods) and analyzed either 
alone or in combination with the K14  /IL1F6   transgene. A 
similar analysis of the   IL1F5  -defi  cient mice was performed 
as described for the   IL1RL2  -defi  cient mice, and no overt 
phenotypes, histopathological abnormalities, or immune cell 
changes were observed. A genetic cross was performed be-
tween K14 /IL1F6  ,  IL1F5    +/  −    mice and  IL1F5      −  /  −    mice. Geno-
typing of the resulting pups at 3 wk of age indicated that 
the K14  /IL1F6  ,   IL1F5      −  /  −    combination was dramatically 
under  represented, with only 1 pup of this genotype out of 109 
total pups surviving at weaning. The other three resulting 
genotypes (K14  /IL1F6  ,   IL1F5    +/  −   ;   IL1F5      −  /  −   ; and   IL1F5    +/  −   ) 
were found in roughly equal numbers. We recovered 13 
dead pups from these crosses between P5 and 10, and all 13 
were K14  /IL1F6  ,   IL1F5      −  /  −   . These pups had milk in their 
stomachs, yet were runted and had a dehydrated appearance. 
Normal skin barrier function as assessed by a dye exclusion 
assay (  33  ) was observed in K14  /IL1F6  ,   IL1F5      −  /  −    at both em-
bryonic day 18.5 and P3 (unpublished data). The surviving 
K14  /IL1F6  ,   IL1F5      −  /  −    mouse that reached adulthood subse-
quently developed severe skin abnormalities. The visible skin 
phenotype of K14  /IL1F6  ,   IL1F5      −  /  −    and K14  /IL1F6  ,   IL1F5    +/  −    
pups was apparent by P3, whereas K14  /IL1F6  ,   IL1F5    +/+   
pups do not have gross skin changes until P5 (  Fig. 5 A   and 
not depicted).   K14  /IL1F6  ,   IL1F5      −  /  −    pups are much smaller 
than their littermates and have severe skin abnormalities 
resembling blisters. K14  /IL1F6  ,   IL1F5    +/  −    pups also have 
extensive regions of thick, scaly skin. Histological analysis 
reveals intracorneal and intraepithelial pustules, parakeratotic 
and orthokeratotic hyperkeratosis, dilated superfi  cial dermal 
blood vessels, and a mixed dermal infl  ammatory infi  ltrate 
(  Fig. 5 B  ). Therefore, the combination of the K14  /IL1F6   
transgene and   IL1F5   defi  ciency results in increased severity 
of the skin phenotype and neonatal lethality. 
  Intraperitoneal injection of newborn K14  /IL1F6  ,   IL1F5      −  /  −    
pups with 50      g M616 at P1, 3, and 5 rescued the neonatal 
lethality. However, upon cessation of antibody treatment, 
adult K14  /IL1F6  ,   IL1F5      −  /  −    and K14  /IL1F6  ,   IL1F5    +/  −    mice 
develop severe lesions on their face, neck, and ears by 4  –  6 wk 
of age. Histological analysis of the K14  /IL1F6  ,   IL1F5      −  /  −    and 
K14  /IL1F6  ,   IL1F5    +/  −    adult skin demonstrates similar features 
as seen in the pups, with the presence of focal   “  plaques  ”   inter-
spersed with regions of normal skin (  Fig. 5 C   and not depicted). 
High magnifi  cation images in   Fig. 5 D   show parakeratotic 
hyperkeratosis and dilated superfi  cial dermal blood vessels with 
a mixed infl  ammatory infi  ltrate. 
    IL1RL2  ,   IL1F6  , and   IL1F5   expression is increased in human 
psoriatic skin 
  Psoriatic plaques and nonlesional skin from 10 patients were 
assayed by in situ hybridization (ISH) with probes specifi  c 
for human   IL1RL2  ,   IL1F6  , and   IL1F5  . Elevated, but low-
level expression of   IL1RL2   was detected throughout the 
epidermis in plaques in 9/10 patients, but not in nonlesional 
  Figure 3.     RP2 and AcP are required receptor subunits for the K14/
  IL1F6     skin phenotype. (A) Skin from 7-d-old K14  /IL1F6 ,   IL1RL2      /         pups 
exhibits hyperkeratosis, increased epidermal thickness, and the presence 
of a dermal infi  ltrate compared with skin from nontransgenic littermates. 
In contrast, skin from 7-d-old K14  /IL1F6 ,   IL1RL2        /         pups does not exhibit 
any of the skin abnormalities. (B) Skin from 7-d-old K14  /IL1F6 ,  AcP       /        
pups lack the skin phenotype of K14  /IL1F6 ,  AcP     /         littermates. (C) K14  /
IL1F6   transgenic pups injected intraperitoneally with a blocking antibody 
against mouse RP2 (M616) lack the skin phenotype observed in K14  /IL1F6  
littermates treated with an isotype-matched control antibody. HE staining 
shown is from skin of 7-d-old pups. (D) Skin from 7-d-old K14  /IL1F6 , 
IL-1R        /         pups has equivalent or more severe skin abnormalities than skin 
from K14  /IL1F6 ,  IL-1R     /         littermates. Images from nontransgenic pup 
skin in B and D are not shown, but are similar to those in A. Bars, 100      m.   JEM VOL. 204, October 29, 2007 
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skin (  Table I  ).   No   IL1RL2   expression was detected in either 
plaques or normal skin in the 10th patient.   IL1F6   expression 
was strongly detected in the superfi  cial layers of the epider-
mis in plaques from skin in all 10 patients, but was either 
not detectable or was only weakly detectable in nonlesional 
skin samples (  Fig. 6, A and B  ;   Table I  ).     IL1F5   is expressed 
in both psoriatic plaques and in nonlesional skin from all 
  patients (  Fig. 6 C  ,   Table I  ).   IL1F5   expression was found 
throughout the epidermis, with a stronger signal in the 
superfi  cial layers.   IL1F5   expression appeared to be higher in 
plaques compared with nonlesional skin in 3/10 patients, 
was slightly higher in 4/10 patients, and was unchanged in 
3/10 patients.   IL1F5  ,   IL1F6  , and   IL1RL2   expression was 
increased in additional psoriatic skin samples, including sam-
ples of pustular psoriasis, and in several samples of the pso-
riasis-like skin disease pityriasis rubra pilaris, but not in chronic 
eczematous dermatitis or in nummular dermatitis (unpub-
lished data). 
  To provide quantitative evidence for the association of 
  IL1RL2  ,   IL1F5  , and   IL1F6   expression with psoriasis, RT-
PCR analysis was performed on seven paired psoriatic and 
nonlesional skin samples. Higher expression of  IL1RL2  ,  IL1F5  , 
and   IL1F6   mRNAs was observed in all psoriatic skin samples 
compared with their corresponding paired nonlesional skin 
(  Fig. 6 D  ). In addition, there was a correlation between the 
expression levels of the three genes in individual patients 
(unpublished data). We conclude that   IL1RL2  ,   IL1F5  , and 
  IL1F6   expression is increased in psoriasis. 
    DISCUSSION   
  The IL-1 ligand superfamily has recently been expanded by 
the discovery of seven new members (  23, 34  ). Three of these 
ligands (IL-1F6, -1F8, and -1F9) activate signaling pathways 
in vitro in an RP2- and AcP-dependent manner (  27, 28  ). 
However, the in vivo function of these molecules has re-
mained obscure. We demonstrate that transgenic expression 
of IL-1F6 in basal keratinocytes leads to skin changes aff  ect-
ing both the epidermis and dermis. 
  Figure 4.     Mechanistic requirements for the K14  /IL1F6   skin pheno-
type. An antibody against TNF-      results in decreased epidermal thick-
ness (A) and decreased dermal infl  ammation ranking (B) in skin from 
7-d-old K14  /IL1F6   transgenic pups (  n        7) compared with K14  /IL1F6  
transgenic skin from pups treated with a control antibody (  n        12). 
(C) An antibody against CD18 (anti-Gr1) results in a decreased dermal 
infl  ammatory ranking in 7-d-old K14  /IL1F6   transgenic pup skin (  n        5) 
compared with a control antibody (  n        6). *, P           0.05; **, P           0.01;  ***, 
P           0.001. Error bars represent the mean       the SEM. (D) HE staining of 
K14/  IL1F6   transgenic pup skin indicating a reduced dermal infl  ammation 
in anti-Gr1 antibody compared with control antibody, but no change in 
epidermal thickness. (E)   RAG2   is not required for the skin phenotype in 
K14  /IL1F6   pups. HE staining of skin from 7-d-old K14  /IL1F6 ,   RAG2      /         and 
K14  /IL1F6 ,   RAG2        /         pups is shown. IHC with anti-CD3 demonstrates the 
absence of mature T lymphocytes in   RAG2        /         pups. IHC with anti  –  ICAM-1 
shows that infl  ammation is not reduced in K14  /IL1F6 ,   RAG2        /         pups. 
Bar, 100      m.   
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  Figure 5.     IL-1F5 is an antagonist of IL-1F6 in vivo. (A) K14  /IL1F6   pups 
with reduced   IL1F5   gene dosage exhibit an altered gross appearance 3 d after 
birth. The skin phenotype and runting are most severely affected in K14  /IL1F6   
Tg     ,   IL1F5        /       pups. From left to right: K14  /IL1F6   Tg     ,   IL1F5      /     ;  K14 /IL1F6   Tg     , 
  IL1F5      /     ; K14  /IL1F6   Tg      ,   IL1F5      /      . (B) K14  /IL1F6   pups with reduced   IL1F5   gene 
dosage have a thickened epidermis, increased dermal infi  ltrate, and parakerato-
sis compared with K14  /IL1F6 ,   IL1F5      /       pups. HE staining of skin is from 3-d-old 
pups. (C) Adult K14  /IL1F6 ,   IL1F5      /       mice have skin abnormalities, whereas K14  /
IL1F6 ,   IL1F5      /       mice do not. HE staining of skin is from 14-wk-old mice. (D, left) 
K14/  IL1F6 ,   IL1F5      /       skin exhibits parakeratotic hyperkeratosis; note the nucle-
ated keratinocytes in the corneal layer (arrowhead). (right) K14/  IL1F6 ,   IL1F5      /      
skin contains dilated superfi  cial dermal blood vessels (arrowheads) and a mixed 
infl  ammatory infi  ltrate composed predominantly of neutrophils and macro-
phages, with fewer lymphocytes and rare eosinophils. Bars, 100      m.    
  Figure 6.        IL1RL2    ,       IL1F5    , and     IL1F6         expression is increased in 
human psoriatic skin. (A) HE staining of psoriatic skin and nonlesional skin 
from the same patient are shown. (B)   IL1F6   is up-regulated in psoriatic 
skin compared with nonlesional skin.   IL1F6   expression is observed only in 
the upper spinous layer of the epidermis. (C)   IL1F5   expression is detected 
in both psoriatic skin and nonlesional skin. However, the   IL1F5   ISH  signal 
is stronger in the psoriatic skin than in the nonlesional skin in the ex-
ample shown. Green staining is autofl  uorescence from keratins. Bar, 100 
     m. (D) Quantitative RT-PCR data for   IL1RL2 ,   IL1F5  , and   IL1F6   expression 
from psoriatic and nonlesional skin from seven patients. *, P       0.05; **, 
P       0.01; ***, P       0.001. Error bars represent the mean       the SEM.     JEM VOL. 204, October 29, 2007 
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K14/  IL1F6   expression results in increased expression in the 
skin of the two other agonistic ligands that activate RP2, 
IL-1F8 and -1F9 (  Fig. 2 A  ). It is possible that the activity 
of IL-1F8 and -1F9 contribute to the skin phenotype, and 
that their decreased expression from P1 to 21 could be part 
of the resolution process. Third,   IL1RL2   expression in the 
skin is slightly decreased after P3 (  Fig. 2 B  ), and could play a 
role in resolution. Fourth, there is decreased expression of 
infl  ammatory cytokines and chemokines over the time course 
(  Fig. 2 C  ). Fifth, dramatic developmental changes in the skin 
occur in the same timeframe that phenotypic resolution is 
initiated. At this time, epidermal thickness decreases and hair 
growth is initiated. Interestingly, K14  /IL1F6   mice with re-
duced   IL1F5   gene dosage have recurrence of skin lesions at 
4  –  6 wk of age, which is months earlier than in K14  /IL1F6  , 
  IL1F5    +/+   mice. Recently, we found that topical administra-
tion of 12-  O  -tetradecanoylphorbol-13-acetate to back skin 
of 8-wk-old K14  /IL1F6   mice results in reactivation of the 
skin phenotype within 3 d (unpublished data). Therefore, de-
creased IL-1F5 antagonist gene dosage or topical 12-  O  -tetra-
decanoylphorbol-13-acetate administration can override the 
normal resolution process. 
  K14  /IL1F6  ,   IL1F5    +/  −    and K14  /IL1F6  ,   IL1F5      −  /  −    skin 
have several histological hallmarks of psoriasis, as follows: 
acanthosis, hyperkeratosis, parakeratosis, intracorneal and in-
traepithelial pustules, presence of a mixed dermal infi  ltrate, 
and dilation of superfi  cial dermal blood vessels. Additionally, 
  IL1RL2  ,   IL1F5  , and   IL1F6   are up-regulated in psoriatic 
skin compared with nonlesional skin from the same patients. 
However, several features in the K14/IL-1F6 mice or in 
K14/IL-1F6, IL-1F5    −  /  −    mice are diff  erent from those in pso-
riasis. Histological features present in psoriasis that are lacking 
in these mice are the presence of rete ridges, the absence of 
the granular layer, and the predominance of lymphocytes in 
the infi  ltrate. In addition, the skin abnormalities in the trans-
genic mice are independent of mature lymphocytes, which 
are a critical immune cell type in psoriasis. Also, TNF-      
blockade has a modest eff  ect on the K14  /IL1F6   skin pheno-
type, but is an eff  ective treatment for psoriasis (  29  ). 
  We hypothesize that the balance between IL-1F agonism 
and IL-1F5 antagonism is critical in skin infl  ammation (  Fig. 7  ).   
Although we describe this model with IL-1F6, it is possible 
  K14  /IL1F6   pups have skin defects with changes in both 
keratinocyte proliferation and diff  erentiation. Epidermal hy-
perplasia is observed as demonstrated by up-regulation of K6 
(  Fig. 1 C  ) and phosphorylation of histone H3 (unpublished 
data) (  35  ). K14  /IL1F6   pups with decreased   IL1F5   gene dos-
age have more severe epidermal hyperplasia than K14  /IL1F6   
pups with a full complement of   IL1F5   (  Fig. 5 B  ). Diff  erentia-
tion defects include expression of K14 in the suprabasal layer 
in K14  /IL1F6   pups (  Fig. 2 E  ) and parakeratosis observed in 
K14  /IL1F6  ,   IL1F5      −  /  −    pups (  Fig. 4 D  ). Additionally, we have 
observed an increased number of CD205  +   Langerhans or 
dermal dendritic cells, CD3  +   T lymphocytes, macrophages, 
and neutrophils in the K14  /IL1F6   pup skin. The infl  amma-
tion marker ICAM-1 is increased in expression in both basal 
keratinocytes and in dermal cells. We have demonstrated that 
inhibition of TNF-     , reduction of neutrophil numbers, or 
the absence of mature lymphocytes cannot completely block 
the skin phenotype. 
  Alterations in the skin caused by K14  /IL1F6   expression 
are distinct from those generated in K14/  IL1A       and K14/  IL18   
transgenic mice. Both K14  /IL1F6   and K14/  IL1A       mice have 
an increase in the number of dermal macrophages, whereas 
only the K14  /IL1F6   mice have increases in epidermal thick-
ness and in the number of neutrophils and CD205  +   cells (  11  ). 
K14/  IL18   mice have features resembling atopic dermatitis 
(  12  ), whereas the K14  /IL1F6  ,   IL1F5    +/  −    mice have some 
similarities with psoriasis, but lack several of its histological 
hallmarks. In addition, the K14/  IL1A       and K14/  IL18   skin 
phenotypes fi  rst occur in adult mice, whereas the K14  /IL1F6   
skin abnormalities occur within 1 wk after birth. 
  An intriguing feature of the K14  /IL1F6   phenotype is that 
it arises shortly after birth, is resolved by 3 wk of age, and 
then spontaneously recurs in 6-mo-old mice. Several factors 
may contribute to the resolution process. First, it appears that 
  IL1F6   transgene expression is silenced by P10 (  Fig. 2 E  ). The 
K14 promoter construct used does have expression diff  er-
ences with the endogenous   KRT14   gene (unpublished data) 
(  36  ). However, this K14 promoter cassette has been used to 
generate skin phenotypes that do not resolve (unpublished 
data) (  36  ,   37  ). This result suggests that the observed resolu-
tion of the K14/  IL1F6   skin phenotype is caused by the RP2/
IL-1F axis, and not by the K14 expression cassette. Second, 
    Table I.        Expression of   IL1RL2 ,   IL1F6  , and   IL1F5   is increased in psoriatic skin 
Gene PS      a      NLS      b     
 No.  patients 
with expression
Mean expression score 
(range)
SD of score   No. patients 
with expression
Mean expression 
score (range)
SD of score No. patients 
with 
  PS       NLS
  IL1RL2 9/10 0.9  (0  –  1.0) 0.32 0/10 0 0 9/10
  IL1F6 10/10 3.3  (1.5  –  5.0) 1.38 1/10 0.1 (0–1.0) 0.32 10/10
  IL1F5 10/10 2.8  (2.0  –  3.0) 0.48  10/10 1.8  (1.0–3.0) 0.75 7/10
  ISH was performed on skin from 10 psoriasis patients. Both psoriatic and nonlesional skin from the same patients was analyzed. Antisense and sense probes were used, and only 
the antisense probes gave rise to a positive signal. Staining intensity was scored from 0 (no staining) to 5.0 (very strong staining).
     a   PS,  psoriatic  skin.
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  Generation of transgenic mice and genetic crosses.     The K14  /IL1F6   
Kpn1 fragment was microinjected at a concentration of 2 ng/ml in 10 mM 
Tris and 0.1 mM EDTA, pH 8.0 into the pronuclei of mouse embryos ob-
tained from B6D2F1 female mice bred to B6D2F1 male mice (Taconic), and 
implanted into pseudopregnant Swiss-Webster (Taconic) recipients. Mice 
were genotyped by PCR with primers in the human growth hormone 
(hGH) polyA region to screen for founders. Transgenic expressers were de-
termined using quantitative RT-PCR analysis of tail skin biopsies from 
7-wk-old founders. Total tail skin RNA was isolated using the RNAeasy Midi 
kit (Qiagen). RT-PCR was performed using a Taqman Reverse Transcrip-
tion Reagents kit (Applied Biosystems). Expression levels were determined 
by the expression of an   GH1   probe (Amgen) relative to   GAPDH   (Applied 
Biosystems). The highest expressers were developed into lines by backcross-
ing to C57BL/6 mice (Taconic). Genotyping for   IL1RL2  ,   IL1RAP  ,   IL1R1  , 
  IL1F5  ,   TNFRSF1A  , and   RAG2   was by standard PCR procedures. 
  Mouse sources.       IL1R  -defi  cient mice on a C57BL/6 background have 
been previously described (  14, 15  ). C57BL/6 and   RAG2    –  defi  cient mice 
(B6.129S6-  RAG2    tm1Fwa  N12) were obtained from Taconic.   IL1RAP  -defi  -
cient mice (B6; 129S1- Il1rap    tm1Rom1  /J) were obtained from Jackson Immuno-
Research Laboratories. Mice lacking   IL1RL2   and   IL1F5   were generated 
by homologous recombination in 129-derived ES cells (Lexicon Genetics). 
In brief, exons 1  –  3 of the   IL1F5   gene and exons 2  –  4 of the   IL1RL2   gene 
were replaced with a lacZneo cassette. Targeted ES clones were identifi  ed by 
Southern blot analyses and injected into C57BL/6 blastocysts. The resulting 
chimeras were crossed to C57BL/6 to generate B6;129 F1 heterozygotes, 
which were intercrossed to generate B6;129 F2 homozygotes. The mutants 
used throughout these studies are on a random hybrid B6;129 genetic back-
ground. All protocols used in these studies were in compliance with federal 
guidelines and the Amgen Institutional Animal Care and Use Committee. 
  Quantitative RT-PCR expression analysis.     Quantitative RT-PCR was 
performed using a Taqman Reverse Transcription Reagents kit (Applied Bio-
systems). Expression levels for the following genes were determined by 
their expression using the following primers and probes, which were de-
signed in-house (Amgen) relative to mouse   ACTB   (Applied Biosystems): 
  IL1F5  ,   IL1F6  ,   IL1F8  ,   IL1F9  ,   IL1RL2  ,   IL23A  ,   CSF2  , and   IL1A      . Prede-
signed Taqman Gene Expression Assays (Applied Biosystems) were used for 
the following genes:   IL1RAP  ,   TNF      ,   CCL2  ,   KRT14  ,   CXCL2  ,   TGA2      , 
  HBEGF  , and   AREG  . 
  Histopathological analysis.     Standard histopathologic examination was 
performed on skin samples fi  xed in 10% neutral buff  ered formalin, processed 
routinely, and stained with hematoxylin and eosin (HE). IHC was performed 
on selected skin sections using the following antibodies: 2.5      g/ml K6 (Co-
vance), 50 ng/ml K14 (Covance), 2      g/ml CD54 (ICAM-1; Millipore), 
10      g/ml CD205 (DEC205; Serotec), 5      g/ml CD3 (DakoCytomation), 
20      g/ml F4/80 (BM8; Serotec), and 15      g/ml IL-1F6 (Amgen). IHC for 
CD54 and CD205 were performed on skin samples fi  xed with Zinc-Tris 
buff  er (0.1 M Tris, pH 7.4) rather than formalin because of sensitivity of the 
antigens to protein cross-linking. All other antibodies were used on forma-
lin-fi  xed, paraffi   n-embedded samples. IHC for keratin 6 and F4/80 required 
antigen retrieval for 5 min with proteinase K. 
  Epidermal thickness was measured on formalin-fi  xed, paraffi   n-embed-
ded samples of back skin stained with HE. For each animal, a digital photo-
graphic image was taken using the 20  ×   microscope objective in the area of 
maximal epidermal thickening, and the epidermal thickness from the bottom 
of the keratin layer to the epidermal basement membrane was measured in 
micrometers at three locations on each image using the caliper function of 
MetaVue morphometry software (Universal Imaging Corporation). The 
three measurements were averaged to determine the maximal epidermal 
thickness for each animal. The group mean and SD were calculated using the 
mean epidermal thickness for each individual as a single value. Skin samples 
were blinded and mixed randomly before image fi  eld selection and while 
taking epidermal measurements. Infl  ammation severity ranking was done on 
that other IL-1 family ligands are also involved. In the model, 
IL-1F5 antagonism prevails and infl  ammation is minimal in 
the skin of wild-type mice. Shifting the balance to favor IL-
1F6 agonism is proposed to result in activation of signaling 
through RP2/AcP, induction of cytokine and chemokine 
expression in the skin, and recruitment of neutrophils and 
macrophages (  Fig. 7 A  ). This can be accomplished by trans-
genic expression of   IL1F6   and can be further skewed by 
combining   IL1F6   transgenic expression with decreased ex-
pression of   IL1F5   (  IL1F5    +/  −    or   IL1F5      −  /  −   ), resulting in a 
more severe skin pathology (  Fig. 7 B  ). Future studies will 
be required to understand the role of this axis in human 
skin disease. 
    MATERIALS AND METHODS   
  Plasmid construction.     The pHR2 plasmid containing the human K14 
(K14) promoter was a kind gift of S. Werner (Institute of Cell Biology, Zur-
ich, Switzerland) (  37  ). The unique Sma1 cloning site for cDNA insertion 
was converted to an Fse1/Pme1/Asc1 polylinker to create pHB137-9. 
Mouse   IL1F6   (GenBank accession no.   NM_019450  ) was used as a template 
for the polymerase chain reaction (PCR) to generate the open reading frame 
(166  –  644 in NM_019450) fl  anked by a 5      Fse1 site and a consensus transla-
tion initiation sequence, and a 3      Asc1 site directly after the stop codon. This 
fragment was inserted in pHB137-9 digested with Fse1/Asc1 to yield 
pHB225-1. Nucleotide sequencing confi  rmed that the PCR fragment was 
identical to the template sequence. The K14/mouse   IL1F6  /hGH poly A 
expression cassette was excised from pHB225-1 with Kpn1, to eliminate 
bacterial sequences from the microinjection fragment. 
  Figure 7.     Model for the role of IL-1F6 and -1F5 in the K14/  IL1F6   
skin phenotype. (A) Proposed mechanism of action (MOA) for IL-1F6 and 
-1F5 in the regulation of a competent signaling complex containing RP2 
and AcP, and downstream events. IL-1F6 activates a receptor complex, 
resulting in signal transduction, induction of cytokine and chemokine 
expression, and mobilization of neutrophils and macrophage into the 
dermis. This process is antagonized by IL-1F5. (B) Model for the critical 
balance between IL-1F6 and -1F5 expression in pup skin infl  ammation. In 
wild-type pups, a balance between IL-1F6 agonist activity and IL-1F5 
antagonist activity results in normal skin. Increasing IL-1F6 expression by 
transgenic expression in an   IL1F5      /       background tips the balance toward 
skin infl  ammation. Reducing   IL1F5   gene dosage (  IL1F5      /        ) in the K14  /IL1F6   
mice exacerbates skin infl  ammation. Complete deletion of   IL1F5   further 
shifts the balance in K14  /IL1F6   mice, resulting in an even more severe 
infl   ammation.   JEM VOL. 204, October 29, 2007 
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resultant P values were adjusted using the stepdown Sidak procedure for mul-
tiple comparisons by each gene. In   Fig. 4 A  , P value was calculated by analysis 
of variance and contrasting between indicated groups. In   Fig. 4 (B and C)  , 
the eff  ect of genotype on dermal infl  ammation ranking was tested by a two-
sample   t   test. In   Fig. 6 D  , log transformation was applied to the 2E-DCT to 
improve normality. Paired   t   tests were used for comparison between PS and 
NLS on log-transformed IL1RL2 and IL1F5 data. A Wilcoxon signed rank 
test was used for F6 because of the nonnormal distribution of the data. 
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